Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
NCT01408043 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2019-06-14
Summary
This clinical trial studies etoposide, filgrastim and plerixafor in improving stem cell mobilization in patients with non-Hodgkin lymphoma. Giving colony-stimulating factors, such as filgrastim, and plerixafor and etoposide together helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored.
Conditions
- Adult Acute Lymphoblastic Leukemia in Remission
- Adult Grade III Lymphomatoid Granulomatosis
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Anaplastic Large Cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- Cutaneous B-cell Non-Hodgkin Lymphoma
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Hepatosplenic T-cell Lymphoma
- Nodal Marginal Zone B-cell Lymphoma
- Noncutaneous Extranodal Lymphoma
- Peripheral T-cell Lymphoma
- Recurrent Adult Burkitt Lymphoma
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Adult Diffuse Mixed Cell Lymphoma
- Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Recurrent Adult Grade III Lymphomatoid Granulomatosis
- Recurrent Adult Immunoblastic Large Cell Lymphoma
- Recurrent Adult Lymphoblastic Lymphoma
- Recurrent Adult T-cell Leukemia/Lymphoma
- Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Mycosis Fungoides/Sezary Syndrome
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Hairy Cell Leukemia
- Small Intestine Lymphoma
- Splenic Marginal Zone Lymphoma
- T-cell Large Granular Lymphocyte Leukemia
- Testicular Lymphoma
- Waldenström Macroglobulinemia
Interventions
- DRUG
-
plerixafor
Given SC
- BIOLOGICAL
-
Given SC
- DRUG
-
etoposide
Given IV
- PROCEDURE
-
leukapheresis
Undergo apheresis
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Case Comprehensive Cancer Center
lead OTHER
Principal Investigators
-
Navneet Majhail, MD · Case Comprehensive Cancer Center
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 78 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-10-31
- Primary Completion
- 2016-05-31
- Completion
- 2016-05-31
Countries
- United States
Study Locations
More Related Trials
-
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
NCT02098109 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
NCT03136146 ·Status: RECRUITING ·Phase: PHASE2
-
Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
NCT00002880 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT00032019 ·Status: COMPLETED ·Phase: PHASE2
-
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
NCT00074282 ·Status: COMPLETED ·Phase: PHASE2
-
High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma
NCT02531841 ·Status: UNKNOWN ·Phase: PHASE3
-
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00073918 ·Status: COMPLETED ·Phase: PHASE2
-
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)
NCT00096460 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma
NCT06561425 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL
NCT01527422 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant
NCT01431209 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
NCT00006125 ·Status: COMPLETED ·Phase: PHASE2
-
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00068315 ·Status: COMPLETED ·Phase: PHASE1
-
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)
NCT01300156 ·Status: UNKNOWN ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
NCT00049439 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
NCT00001337 ·Status: COMPLETED ·Phase: PHASE2
-
Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00062296 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
NCT01132807 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
NCT00005964 ·Status: COMPLETED ·Phase: PHASE2
-
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
NCT01415765 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
NCT07224100 ·Status: RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma
NCT00041327 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
NCT02181218 ·Status: COMPLETED ·Phase: PHASE1
-
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
NCT00005803 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease
NCT00003114 ·Status: COMPLETED ·Phase: PHASE2